Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women
Autor: | Hadine Joffe, Helga Arsenio, Lee S. Cohen, Claudio N. Soares, Bettina Bankier, Laura F. Petrillo, Paolo Cassano |
---|---|
Rok vydání: | 2006 |
Předmět: |
Adult
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Citalopram Ethinyl Estradiol law.invention Randomized controlled trial law Internal medicine medicine Humans Escitalopram Depression (differential diagnoses) Psychiatric Status Rating Scales Gynecology Progestogen Depression business.industry Obstetrics and Gynecology Estrogens Middle Aged Perimenopause Postmenopause Vasomotor System Norethindrone Acetate Treatment Outcome Tolerability Estrogen Hot Flashes Quality of Life Antidepressive Agents Second-Generation Female Hormone therapy Norethindrone Sleep Climacteric business medicine.drug |
Zdroj: | Menopause. 13:780-786 |
ISSN: | 1072-3714 |
DOI: | 10.1097/01.gme.0000240633.46300.fa |
Popis: | To examine the efficacy and tolerability of escitalopram (ESCIT) compared to estrogen and progestogen therapy (EPT) for the treatment of symptomatic peri- and postmenopausal women.Forty women (aged 40-60 years) with depressive disorders and menopause-related symptoms were randomly assigned to an 8-week open trial with ESCIT (flexible dose, 10-20 mg/day; fixed dose, 10 mg/day for the first 4 weeks) or estrogen plus progestogen therapy (ethinyl estradiol 5 microg/day plus norethindrone acetate 1 mg/day). Primary outcome measures included Montgomery-Asberg Depression Rating Scale and the Greene Climacteric Scale at week 8. Secondary outcome measures included the Clinical Global Impressions as well as sleep and quality of life assessments.Thirty-two women (16 on EPT, 16 on ESCIT) were included in the analyses. Full remission of depression (score of10 on the Montgomery-Asberg Depression Rating Scale) was observed in 75% (12/16) of subjects treated with ESCIT, compared to 25% (4/16) treated with EPT (P = 0.01, Fisher's exact tests). Remission of menopause-related symptoms (50% decrease in Greene Climacteric Scale scores) was noted in 56% (9/16) of women treated with ESCIT compared to 31.2% (5/16) on EPT (P = 0.03, Pearson's chi2 tests). Improvement in sleep, hot flashes, and quality of life was observed with both treatments.ESCIT is more efficacious than EPT for the treatment of depression and has a positive impact on other menopause-related symptoms. ESCIT may constitute a treatment option for symptomatic menopausal women who are unable or unwilling to use hormone therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |